Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Non-Current Deffered Revenue: 2019-2024

Historic Non-Current Deffered Revenue for Avidity Biosciences (RNA) over the last 6 years, with Dec 2024 value amounting to $38.0 million.

  • Avidity Biosciences' Non-Current Deffered Revenue fell 24.12% to $32.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.1 million, marking a year-over-year decrease of 24.12%. This contributed to the annual value of $38.0 million for FY2024, which is 7.18% down from last year.
  • According to the latest figures from FY2024, Avidity Biosciences' Non-Current Deffered Revenue is $38.0 million, which was down 7.18% from $40.9 million recorded in FY2023.
  • Over the past 5 years, Avidity Biosciences' Non-Current Deffered Revenue peaked at $40.9 million during FY2023, and registered a low of $1.2 million during FY2022.
  • For the 3-year period, Avidity Biosciences' Non-Current Deffered Revenue averaged around $26.7 million, with its median value being $38.0 million (2024).
  • Per our database at Business Quant, Avidity Biosciences' Non-Current Deffered Revenue crashed by 81.09% in 2022 and then surged by 3,211.58% in 2023.
  • Yearly analysis of 5 years shows Avidity Biosciences' Non-Current Deffered Revenue stood at $12.2 million in 2020, then tumbled by 46.24% to $6.5 million in 2021, then slumped by 81.09% to $1.2 million in 2022, then surged by 3,211.58% to $40.9 million in 2023, then dropped by 7.18% to $38.0 million in 2024.